Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.86 |
| ▸ | MEN1 | O00255 | 2/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.86 |
| ▸ | HPGD | P15428 | 2/20 | 0.86 |
| ▸ | PDE1A | P54750 | 2/20 | 0.86 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.86 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.86 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.77 |
| ▸ | PDE6C | P51160 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | PDE2A | O00408 | 1/20 | 0.58 |
| ▸ | PDE6D | O43924 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | PDE9A | O76083 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31202656 | 1.00 | PDE5A (0.86) | PDE5AKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL6718781 | 0.95 | PDE5A (0.85) | PDE5AKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL31174349 | 0.93 | PDE5A (1.00) | PDE5AKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL1202 | 0.93 | PDE5A (1.00) | PDE5AKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL6716699 | 0.91 | PDE5A (0.79) | PDE5AKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL3316795 | 0.89 | PDE5A (0.82) | PDE5AKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL6719476 | 0.89 | PDE5A (0.81) | PDE5AKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL1160 | 0.88 | PDE5A (0.80) | PDE5AKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL5462416 | 0.88 | PDE5A (0.67) | PDE5AKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL7965689 | 0.87 | PDE5A (0.67) | PDE5AKMT2AMEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219220-A1 | Pyrazolopyrimidinethione Derivatives, Salts and Solvates Thereof, Preparation Methods and Use Thereof | THE INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) | 2007-09-20 | — | — | US | disclosed |
| EP-1695976-A1 | PYRAZOLOPYRIMIDINETHIONE DERIVATIVES, SALTS AND SOLVATES THEREOF, PREPARATION METHODS AND USE THEREOF | Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla (CN) | 2006-08-30 | — | — | EP | disclosed |
| US-20040176371-A1 | Novel pyrazolopyrimidinethione derivatives, preparation methods thereof and their use as therapeutics for erectile dysfunction | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-09-09 | — | — | US | disclosed |
| US-6200980-B1 | ADMINISTERING PHENYL PURINONE COMPOUND FOR TREATING PRECANCEROUS LEISONS | CELL PATHWAYS, INC. | 2001-03-13 | — | — | US | disclosed |
| US-5719283-A | INHIBITORS OF PHOSPHODIESTERASES; CARDIOVASCULAR DISORDERS | PFIZER INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0526004-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1997-10-08 | — | — | EP | disclosed |
| US-5426107-A | Treatment of cardiovascular disorders, asthma, allergies | PFIZER INC. (US) | 1995-06-20 | — | — | US | disclosed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| US-5346901-A | Treatment of angina, hypertension, heart failure and atherosclerosis | PFIZER INC. (US) | 1994-09-13 | — | — | US | disclosed |
| US-5272147-A | Pyrazolopyrimidinone antianginal agents | PFIZER INC. (US) | 1993-12-21 | — | — | US | disclosed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0526004-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1993-02-03 | — | — | EP | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219220-A1 | Pyrazolopyrimidinethione Derivatives, Salts and Solvates Thereof, Preparation Methods and Use Thereof | PDE5A, PDE3B, PDE3A | PDE5A 1/4885KMT2A 3164/4885MEN1 4118/4885 |
| US-20040176371-A1 | Novel pyrazolopyrimidinethione derivatives, preparation methods thereof and their use as therapeutics for erectile dysfunction | PDE3B, PDE3A, PDE5A | PDE5A 3/4885KMT2A 4233/4885MEN1 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.